ROIV Financials: Roivant Sciences Ltd AI Analysis



Financials

ROIV Financial

Roivant Sciences Ltd

$29.83

2.19%

$0.63

At close: Apr 17, 16:00:00 GMT-4

$29.8

-0.1%

$-0.02

Post-market: Apr 17, 20:00:00 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$29.19

Open

$29.56

Day's Range

$29 - $30.18

52 week range

$9.87 - $30.33

Volume

6.0M

Avg.Volume

6.0M

Dividend yield

EPS (TTM)

-1.17

Market Cap

$21.3B

What is ROIV?

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. The company also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

Features

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

ROIV Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	09/30/2025	06/30/2025	03/31/2025	12/31/2024	09/30/2024
Revenue	13,583	3,000	3,205	3,529	3,847	3,600
Revenue Growth (YoY)	-7%	-17%	-6%	0%	-6%	-2%
Cost of Revenue	12,822	2,822	3,020	3,334	3,645	3,390
Gross Profit	760	178	185	195	202	210
Selling, General & Admin	404	92	98	101	111	108
Research & Development	--	--	--	--	--	--
Operating Expenses	770	180	185	194	209	208
Other Non Operating Income (Expenses)	6	7	0	0	0	0
Pretax Income	-28	-1	-7	-7	-12	-3
Income Tax Expense	0	0	0	0	0	0
Net Income	-70	-12	-19	-17	-19	-17
Net Income Growth	-73%	-28.99%	36%	21%	-91%	-82%
Shares Outstanding (Diluted)	174.21	174.21	173.56	173.11	172.76	17.19
Shares Change (YoY)	913%	913%	913%	911%	917%	2%
EPS (Diluted)	-0.4	-0.07	-0.11	-0.1	-0.11	-0.99
EPS Growth	-97%	-93%	-86%	-87%	-99%	-82%
Free Cash Flow	40	38	-61	112	-48	109
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	5.59%	5.93%	5.77%	5.52%	5.25%	5.83%
Operating Margin	-0.06%	-0.06%	0%	0%	-0.18%	0.05%
Profit Margin	-0.51%	-0.4%	-0.59%	-0.48%	-0.49%	-0.47%
Free Cash Flow Margin	0.29%	1.26%	-1.9%	3.17%	-1.24%	3.02%
EBITDA	--	--	--	--	--	--
EBITDA Margin	--	--	--	--	--	--
D&A For EBITDA	--	--	--	--	--	--
EBIT	-9	-2	0	0	-7	2
EBIT Margin	-0.06%	-0.06%	0%	0%	-0.18%	0.05%
Effective Tax Rate	0%	0%	0%	0%	0%	0%

Follow-Up Questions

What are Roivant Sciences Ltd's key financial statements?



According to the latest financial statement (Form-10K), 111 Inc has a total asset of $0, Net loss of $0

What are the key financial ratios for ROIV?



111 Inc's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Roivant Sciences Ltd's revenue broken down by segment or geography?



111 Inc largest revenue segment is Business to Business, at a revenue of 2,044,301,543 in the most earnings release.For geography, China is the primary market for 111 Inc, at a revenue of 2,109,819,132.

Is Roivant Sciences Ltd profitable?



no, according to the latest financial statements, 111 Inc has a net loss of $0

Does Roivant Sciences Ltd have any liabilities?



no, 111 Inc has liability of 0

How many outstanding shares for Roivant Sciences Ltd?



111 Inc has a total outstanding shares of 0

Roivant Sciences Ltd (ROIV) Financial

ROIV Stock Price Chart